Introduction
============

With a total of 989,600 new cancer cases and 738,000 deaths worldwide in 2008, gastric cancer (GC) is the fourth most common malignant tumor and the second most common cause of cancer-related deaths, accounting for 10.4% of cancer-related deaths [@B1], [@B2]. Unfortunately, in China, most gastric cancer patients are diagnosed at an advanced stage of disease, thus precluding the use of curative gastrectomy [@B3]-[@B5]. Multidisciplinary treatment has been applied for gastric cancer patients with improved treatment outcomes in recent years [@B6]. However, gastric cancer is still lacking efficient medicines.

In recent decades, it has been confirmed that tumor progression of GC is a multi-step process that involves the activation of oncogenes and the inactivation of tumor suppressor genes at different stages [@B7], [@B8]. Deregulation of cell cycle progression is considered to be critical for carcinogenesis [@B9]. Uncontrolled cell proliferation is the hallmark of cancer, and genes that directly regulate the cell cycle are typically damaged in tumor cells [@B10]. Endogenous regulation of the cell cycle depends on phosphorylation and dephosphorylation of the cyclin- cyclin-dependent kinase (CDK)-cyclin-dependent kinase inhibitor (CDKI) pathway. Recently, a series of studies revealed the diagnostic and prognostic value of CDKs (mainly CDK1-7) in different types of human cancer, including oral cancer, medulloblastoma, pancreatic cancer [@B11]-[@B14].

Cyclin-dependent kinase (CDK) 10 is a Cdc2-related kinase, which was first described in 1994 as PISSLRE and possesses the hallmark features common to the cyclin-dependent kinase family [@B15], [@B16]. Functional studies by using both antisense and dominant-negative mutant constructs of CDK10 revealed that CDK10 plays an essential role in the progression from the G2 to M phase of the cell cycle [@B17]. Recent studies have shown reduced expression of CDK10 in many types of cancerous human tissue, including hepatocellular carcinoma, breast cancer and biliary tract cancer, demonstrating that CDK10 is a putative new tumor suppressor gene in multiple types of human cancers [@B18]-[@B22]. However, relatively little is known about its expression pattern, clinical relevance, and biological function in GC. Here, we estimate the expression of CDK10 in primary gastric adenocarcinoma by quantitative real-time PCR (qRT-PCR), western blotting and immunohistochemistry and evaluate its clinicopathological and prognostic value to GC patients.

Material and Methods
====================

Ethics statement
----------------

The research was approved by the Ethics Committee of the Sun Yat-sen University Cancer Center, and written informed consent was obtained from each patient involved in the study.

Patients
--------

From January 2005 to December 2010, clinicopathological data from 189 gastric cancer patients who underwent surgical resection at the Sun Yat-sen University Cancer Center were retrospectively analyzed. Patients who met the following eligibility criteria were included: 1) diagnosis of gastric adenocarcinoma identified by histopathological examination; 2) surgical history that included gastrectomy plus D2 lymphadenectomy; 3) availability of complete follow-up data; 4) no preoperative treatment, such as chemotherapy and radiotherapy; 5) no history of familial malignancy or other synchronous malignancy (such as GIST, esophageal cancer, or colorectal cancer); 6) no recurrent gastric cancer or remnant gastric cancer; and 7) no death in the perioperative period. Tumor resection and D2 lymphadenectomy were performed by experienced surgeons, and the surgical procedures, which followed the Japanese Gastric Cancer Association (JGCA) guidelines, were similar in all patients who underwent radical resections.

Fresh gastric cancer and adjacent non-tumor tissue samples were obtained from 48 gastric cancer patients who underwent surgical resection at the Sun Yat-sen University Cancer Center between 2012 and 2013. After surgical resection, fresh tissue samples were immediately immersed in RNAlater (Ambion, Inc., USA) and stored at 4°C overnight to allow thorough penetration of the tissues; the samples were then frozen at -80°C until RNA extraction. Both the tumor tissue and the adjacent non-tumor tissue, which was located more than 2 cm away from the gastric cancer, were sampled and then verified by pathological examination. Paraffin-embedded samples were obtained from the 189 gastric cancer patients who underwent surgical resection at the Sun Yat-sen University Cancer Center between 2005 and 2010. Each tumor sample was assigned a histological grade based on the World Health Organization (WHO) classification criteria. All of the patients were staged using the 7th edition of the International Union Against Cancer (UICC) Tumor-Node-Metastasis (TNM) staging system.

Extraction of total RNA and real-time quantitative PCR
------------------------------------------------------

Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, California, USA) according to the manufacturer\'s protocol. The total RNA concentration was assessed by measuring the absorbance at 260 nm using a NANO DROP spectrophotometer (ND-1000, Thermo Scientific, USA). Reverse transcription (RT) to synthesize the first-strand of cDNA was performed with 2 μg of total RNA treated with M-MLV reverse transcriptase (Promega, USA) according to the manufacturer\'s recommendations. The resulting cDNA was then subjected to real-time quantitative PCR for evaluation of the relative mRNA levels of CDK10 and GAPDH (as an internal control) with the following primers:

CDK10 forward, 5′-TGGACAAGGAGAAGGATG-3′, reverse, 5′-CTGCTCACAGTAACCCATC-3′; GAPDH forward, 5′-CTCCTCCTGTTCGACAGTCAGC-3′, and reverse: 5′-CCCAATACGACCAAATCCGTT-3′. Gene-specific amplification was performed using an ABI 7900HT real-time PCR system (Life Technologies, Carlsbad, California, USA) with 15 μl of PCR mix containing 0.5 μl of cDNA, 7.5 μl of 2 x SYBR Green master mix (Invitrogen, Carlsbad, California, USA), and 200 nM of the appropriate oligonucleotide primers. The mix was preheated to 95°C (10 min) and then amplified at 95°C (30 sec) and 60°C (1 min) for 45 cycles. The resolution curve was measured at 95°C for 15 sec, 60°C for 15 sec and 95°C for 15 sec. The Ct (threshold cycle) value of each sample was calculated from the threshold cycles with the instrument\'s software (SDS 2.3), and the relative expression levels of the target genes were normalized to the geometric mean of the internal control gene GAPDH. Each sample was tested in duplicate, and each experiment was repeated at least twice using cDNA samples from separate reverse transcription reactions. The generated data were averaged and expressed in relative units of normalized expression. The data were analyzed using the comparative threshold cycle (2^-ΔΔCT^) method.

Western blotting analysis
-------------------------

The frozen tissue samples from patients with gastric cancer, including the tumor and non-tumor tissue, were homogenized in RIPA lysis buffer, and the lysates were cleared by centrifugation (12,000 rpm) at 4°C for 15 min. Approximately 40-mg protein samples were run on 12% SDS-PAGE gels and transferred to PVDF membranes. After blocking non-specific binding sites for 60 min with 5% non-fat milk, the membranes were incubated overnight at 4°C with a primary polyclonal antibody against CDK10 (Abcam, USA, at a 1:1000 dilution). The membranes were then washed three times with TBST for 10 min each and probed with an HRP conjugated secondary antibody (Immunology Consultants Laboratory, USA, at a 1:2000 dilution) for 60 min at room temperature. The membranes were then washed three times with TBST and developed with an enhanced chemiluminescence system (ECL, Pierce).

Immunohistochemistry and analysis
---------------------------------

The tissue sections were deparaffinized with dimethylbenzene and rehydrated through 100%, 95%, 90%, 80% and 70% ethanol. After three washes in phosphate-buffered saline (PBS), the slides were boiled in antigen retrieval buffer containing 0.01 M sodium citrate-hydrochloric acid (pH=6.0) for 15 min in a microwave oven. After rinsing with PBS, the tissue sections were incubated with primary antibody, and the slides were then rinsed in a 3% peroxidase quenching solution (Invitrogen) to block endogenous peroxidases. The sections were then incubated with a mouse monoclonal antibody against CDK10 (Abcam, USA, at a 1:500 dilution) at 4°C overnight and then incubated with horseradish peroxidase (HRP) (ChemMateTM DAKO EnVisionTM Detection Kit) at room temperature for 30 min. After washing in PBS, the sections were developed with 3, 3\'-diaminobenzidine (DAB) solution, and all of the slides were counterstained with hematoxylin. As negative controls, adjacent sections were processed as described above, except that they were incubated overnight at 4°C in blocking solution without the primary antibody.

The total CDK10 immunostaining score was calculated as the sum of the percentage of positively stained tumor cells and the staining intensity. Briefly, the percentage of positive staining was scored as 0 (0-9%, negative), 1 (10%-25%, sporadic), 2 (26%-50%, focal) or 3 (51%-100%, diffuse), and the intensity as 0 (no staining), 1 (weak staining), 2 (moderate staining) or 3 (dark staining). The total immunostaining score was calculated as the percent positivity score × the staining intensity score, which ranged from 0 to 9. The expression level of CDK10 was defined as follows: "-" (negative, score 0), "+" (weakly positive, score 1-3), "++" (positive, score 4-6), "+++" (strongly positive, score7-9). Based on the CDK10 expression levels, the gastric cancer patients were divided into two groups: a negative CDK10 expression group (CDK 10-) and a positive CDK10 expression group (CDK10+, CDK10++ and CDK10 +++).

Statistical analysis
--------------------

Differences in mRNA and protein expression between tumor samples and paired adjacent non-tumor tissue samples were evaluated with paired-sample t-tests. The χ^2^ test was used to analyze the relationships between CDK10 expression and various clinicopathological parameters. Survival curves were calculated using the Kaplan-Meier method and compared by the log-rank test. A Cox proportional hazard regression model was used for univariate and multivariate analyses to study the effects of the clinicopathological variables and CDK10 expression on survival. The statistical analyses were performed with the Statistical Package for the Social Sciences, version 17.0 (SPSS Inc., Chicago, IL, USA), and a two-sided P value less than 0.05 was considered statistically significant.

Results
=======

CDK10 mRNA expression analyzed with qRT-PCR
-------------------------------------------

The transcriptional levels of CDK10 were estimated by qRT-PCR assays on 48 pairs of resected specimens (tumor tissue samples and matched adjacent non-tumor tissue samples) from eligible gastric cancer patients. The CDK10 mRNA levels were significantly reduced in 29 (60.4%) tumor tissue samples, compared with the adjacent non-tumor tissue samples (*P*=0.013, Figure [1](#F1){ref-type="fig"}).

CDK10 expression analyzed by Western blotting
---------------------------------------------

CDK10 protein levels in the resected gastric cancer samples were measured by western blotting. We identified a CDK10 band at the expected size of 40 kDa, and quantified the amount of CDK10 protein by densitometry. As shown in Figure [2](#F2){ref-type="fig"}, a decrease in CDK10 expression was detected in 23 (57.5%) of the 40 tumor tissue samples, compared with the matched adjacent non-tumor tissue samples (*P*=0.016, Figure [2](#F2){ref-type="fig"}A and Figure [2](#F2){ref-type="fig"}B). These findings were consistent with the results of qRT-PCR.

The association between levels of CDK10 expression and clinicopathological characteristics, based on immunohistochemical staining
---------------------------------------------------------------------------------------------------------------------------------

To obtain further insight into the effect and prognostic value of CDK10 expression in gastric cancer patients, paraffin-embedded tissue sections (n=189) with histopathologically confirmed gastric adenocarcinoma were examined using immunohistochemistry. We found significant differences in CDK10 immunoreactivity between the tumor tissue and the adjacent non-tumor samples. Positive CDK10 expression was localized to the cytoplasm in 97 (51.3%) tumor tissue samples, whereas the remaining 92 cases (48.7%) displayed reduced cytoplasmic CDK10 expression (Table [1](#T1){ref-type="table"}). Representative photomicrographs are shown in Figure [3](#F3){ref-type="fig"}. Based on the categories defined in the methods section, decreased expression of CDK10 was significantly correlated with the depth of tumor infiltration (T stage, *P*=0.006), local lymph node metastasis (N stage, *P*=0.030), distant metastasis (M) (*P*=0.032) and TNM stage (*P*=0.010), but not with age, gender or tumor size. The result was shown in Table [1](#T1){ref-type="table"}.

Expression of CDK10 and clinical outcome
----------------------------------------

The 5-year overall survival rates in patients with high and low CDK10 expression were 66.0% and 46.7%, respectively. The overall survival of patients with low CDK10 expression was significantly shorter than that of patients with high CDK10 expression (*P*\<0.001, log-rank test, Figure [4](#F4){ref-type="fig"}). Univariate Cox regression analyses showed that the depth of tumor infiltration, local lymph node metastasis, distant metastasis, TNM stage, tumor size and CDK10 expression were significantly interrelated with overall survival (Table [2](#T2){ref-type="table"} and Figure [4](#F4){ref-type="fig"}). Furthermore, a multivariate Cox regression analysis confirmed that distant metastasis (*P*\<0.001) and CDK10 expression (*P*=0.011) were independent predictors of overall survival in patients with gastric adenocarcinoma (Table [2](#T2){ref-type="table"}).

Discussion
==========

Tumor progression arises as a consequence of a series of cellular events, which involve deregulation of the cell cycle [@B22]. Cell cycle progression and cell division are driven by the sequential activation of a group of serine/threonine kinases called cyclin-dependent kinases (CDKs) [@B23]. In complexes that regulate the cell cycle, which consist of cyclin, CDKs and CDKIs, CDKs do not act alone; they gain their activity to trigger cell cycle progression by associating with cyclin subunits, but are negatively regulated by CDKIs [@B24]. This delicate regulatory network ensures the precise timing and coordination of the mechanical events that duplicate and divide the cell.

Reduced expression of CDK10, which plays an essential role in the progression from the G2 to M phase of the cell cycle, has been shown in several types of cancerous human tissue [@B18]-[@B22]. In our study, we found that the expression of CDK10 in tumor tissue is lower than that in adjacent non-tumor tissue according to real-time PCR, western blotting and immunohistochemistry (IHC) analyses. Furthermore, the tumor suppressor role of CDK10 was also investigated in gastric cancer cell lines.

We found that CDK10 expression is lower at both the transcriptional and translational levels in tumor tissue than in adjacent non-tumor tissue. According to IHC, 92 out of 189 cases (48.7%) displayed reduced cytoplasmic CDK10 expression in tumor tissue. Overall, we found that CDK10 expression is reduced or lost in a number of cancer tissues, which is consistent with previous reports on hepatocellular carcinoma, breast cancer and biliary tract cancer.

Furthermore, we found that the decreased expression of CDK10 was significantly correlated with the depth of tumor infiltration (T stage, *P*=0.006), local lymph node metastasis (N stage, *P*=0.030), distant metastasis (M) (*P*=0.032) and TNM stage (*P*=0.010), but not with age, gender or tumor size. In the Kaplan-Meier analysis, CDK10 expression was significantly correlated with overall survival. Multivariate Cox regression analysis confirmed that CDK10 expression (*P*=0.011) was an independent predictor of the overall survival of patients with gastric adenocarcinoma. This is the first time that CDK10 expression was found to be an independent prognostic factor in gastric cancer. Moreover, similar findings were also reported in biliary tract cancer and hepatocellular carcinoma. Taken together, our results demonstrate that CDK10 might serve as a valuable prognostic biomarker and a potential target for future cancer diagnosis and treatments.

Crawford *et al.* first demonstrated that CDK10 contains a PSTAIRE-like motif named PISSLRE, which is most closely related to p58/GTA, the galactosyl transferase associated protein. PISSLRE plays an unexpected role compared with other CDKs, because it acts as an antiproliferative factor [@B18]. Human Cdk10 maps to a region of chromosome 16 (16q24), and high rates of LOH and hypermethylation have been demonstrated in the promoter region of the CDK10 gene in HCC cell lines [@B19]. Iorns *et al.* investigated the molecular mechanism of CDK10 in breast cancer. They found that CDK10 inactivated the c-RAF/MAPK pathway and was an important determinant of resistance to endocrine therapy for breast cancer [@B24]. CDK10 may play similar roles in GC [@B25]. Further understanding of the molecular mechanisms of CDK10 in GC progression is needed to establish the relationship between CDK10 and drug-resistance, which may be important for chemotherapy [@B26], [@B27].

In conclusion, the present study suggests that CDK10 may function as a prognostic marker in gastric cancer and low CDK10 expression independently predicts poorer overall survival in patients. However, the molecular mechanisms involved in the regulation of CDK10 in gastric cancer require further investigation. Moreover, we expect that CDK10, which directly regulates the cell cycle and may participate in other pathways, will become a useful target for new therapeutic interventions against gastric cancer.
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![The CDK10 mRNA levels were significantly reduced in 29 (60.4%) tumor tissue samples, compared with the adjacent non-tumor tissue samples by using Real-time PCR (P=0.013).](jcav08p2907g001){#F1}

![A decrease in CDK10 expression was detected in 23 of the 40 tumor tissue samples, compared with the matched adjacent non-tumor tissue samples by using Western -Blotting. (P=0.016). The band intensity was measured by densitometry using the Quantity One software. The protein levels were normalized to that of GAPDH detected using a mouse anti-human GAPDH monoclonal antibody.](jcav08p2907g002){#F2}

![The expression patterns of CDK10 in gastric carcinoma tissues by IHC. A: High expressed CDK10 in gastric carcinoma tissue, scored as CDK10(+++). B: Moderate expressed CDK10 in gastric carcinoma tissue, scored as CDK10(++). C: Slight expressed CDK10 in gastric carcinoma tissue scored as CDK10(+). D: Negative expressed CDK10 in gastric carcinoma tissue. scored as CDK10(-)](jcav08p2907g003){#F3}

![Kaplan-Meier analyses showed that tumor size(P=0.0011); the depth of tumor infiltration (P=0.005), local lymph node metastasis(P\<0.001), distant metastasis(P\<0.001), TNM stage(P\<0.001), and CDK10 (P\<0.001) expression were significantly interrelated with overall survival. But the age and gender has no correlation with the prognosis of the patients.](jcav08p2907g004){#F4}

###### 

Correlation between CDK10 expression and clinicopathological variables of 189 gastric cancer cases

  Clinicopathological parameters   *n*^a^   CDK10 expression   χ^2^   *P* value   
  -------------------------------- -------- ------------------ ------ ----------- ---------
  All                              189      97                 92                 
  Age (years)                                                                     
  \<55                             83       49                 34     0.060       0.078
  ≥55                              106      48                 58                 
  Gender                                                              1.060       0.303
  Male                             124      67                 57                 
  Female                           65       30                 35                 
  Tumor size                                                          0.005       0.942
  \<3 cm                           25       12                 13                 
  ≥3 cm                            164      84                 80                 
  Tumor infiltration                                                  14.446      0.006\*
  T1                               16       7                  9                  
  T2                               16       12                 4                  
  T3                               4        2                  2                  
  T4a                              111      64                 47                 
  T4b                              42       12                 30                 
  Local lymph node metastasis                                         8.953       0.030\*
  N0                               54       34                 20                 
  N1                               34       18                 16                 
  N2                               32       19                 13                 
  N3                               69       26                 43                 
  Distant metastasis                                                  4.573       0.032\*
  M0                               166      90                 76                 
  M1                               23       7                  16                 
  TNM staging                                                         11.433      0.010\*
  I                                22       11                 11                 
  II                               32       24                 8                  
  III                              112      55                 57                 
  IV                               23       7                  16                 

^a^Numbers of cases in each group. \* Statistically significant (*P*\<0.05).

###### 

Kaplan-Meier univariate survival analyses and multivariate Cox regression analyses of overall survival of gastric cancer patients

  Variables                         *n*^a^   Univariate analyses   Multivariate analyses                                          
  --------------------------------- -------- --------------------- ----------------------- ----------- --------- ---------------- -----------
  **Overall**                                48.168                44.163-52.192                                                  
  **Age (years)**                                                                          0.716                                  
  \<55                              83       46.881                41.266-52.497                                                  
  ≥55                               106      47.470                42.069-52.871                                                  
  **Gender**                                                                               0.749                                  
  Female                            65       47.321                40.693-53.948                                                  
  Male                              124      48.347                43.333-53.361                                                  
  **Tumor size**                                                                           0.012\*                                0.705
  \<3 cm                            25       63.296                55.135-71.457                       1.000                      
  ≥3 cm                             164      45.335                41.048-49.623                       0.817     0.287-2.328      
  **Tumor infiltration**                                                                   0.005\*                                0.394
  T1                                16       \#                    \#                                  1.000                      
  T2                                16       64.500                56.045-72.955                       \<0.001   0.000-4.95E268   
  T3                                4        \#                    \#                                  0.233     0.053-1.029      
  T4a                               111      45.664                40.639-50.689                       0.465     0.267-0.853      
  T4b                               42       31.564                3.821                               0.763     0.471-1.238      
  **Local lymph node metastasis**                                                          \<0.001\*                              0.081
  N0                                54       61.410                55.366-67.454                       1.000                      
  N1                                34       48.543                39.843-57.244                       0.494     0.236-0.922      
  N2                                32       47.641                39.079-56.202                       0.540     0.249-1.003      
  N3                                69       34.614                28.364-40.864                       0.620     0.331-1.161      
  **Distant metastasis**                                                                   \<0.001\*                              \<0.001\*
  M0                                166      52.059                47.986-56.133                       1.000                      
  M1                                23       17.696                11.166-24.225                       4.361     2.589-7.345      
  **TNM staging**                                                                          \<0.001\*                              
  I                                 22       \#                    \#                                                             
  II                                32       55.344                48.062-62.625                                                  
  III                               112      44.441                39.562-49.319                                                  
  IV                                23       17.696                11.166-24.225                                                  
  **CDK10**                                                                                \<0.001\*                              0.011\*
  Positive                          97       54.461                49.431-59.491                       1.000                      
  Negative                          92       40.912                34.954-46.870                       0.561     0.360-0.877      

HR, hazard ratio; CI, confidence interval; ^a^ Numbers of cases in each group; \* Statistically significant (*P* \< 0.05). \#, all of these patients survive, median survival time cannot be calculated.
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